论文部分内容阅读
第三代抗生素——托普霉素第三代抗生素——托普霉素原料药和注射液经河北制药厂与中国科学院共同研制成功,并通过鉴定,该产品属国家“七五”重点攻关项目。该药经八家医院临床验证:对革兰氏阴性菌、葡萄球菌感染的泌尿系统、下呼吸道、皮肤组织及关节炎、胃肠、败血症等疾患有效率达88.5％,在治疗范围,治疗效果,无毒副作用等方面优于国内同类抗生素,质量达到国际水平,标志着我国抗生素生产进入了一个新阶段。
The third generation of antibiotics - the third generation of tobramycin antibiotics - tobramycin API and injection by the Hebei Pharmaceutical Factory and the Chinese Academy of Sciences jointly developed and passed the appraisal, the product is the country “Seventh Five-Year” key research project. The drug has been clinically proven in eight hospitals: the effective rate is 88.5% for Gram-negative bacteria, Staphylococcus aureus urinary system, lower respiratory tract, skin tissue and arthritis, gastrointestinal, septicemia and other diseases. In the treatment range, the treatment effect , Non-toxic side effects and other domestic antibiotics better than the quality of the international level, marking China’s antibiotic production has entered a new phase.